Bile Duct Cancer Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to bile duct cancer market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Bile Duct Cancer Market News

in Bile Duct Cancer
  • In January 2025, the University College London Hospitals and UCL announce the launch of a new precision medicine study. The study aims to enhance survival rates for patient diagnosed with biliary tract cancer. The study also focuses on customizing the treatments based on the genetic profile of each patient's cancer cell.
  • In November 2024, the U.S. Food and Drug Administration announced the approval of Zanidatamab for the treatment of advanced and metastatic Biliary Tract Cancers with High HER2 Levels.
  • In November 2024, Roche announced the U.S. Food and Drug Administration (FDA) approval for Ziihera. It is a bispecific HER2-targeted antibody developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable biliary tract cancer.

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Bile Duct Cancer Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.91 billion in 2024 to USD 7.5 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

To remain competitive in the Bile Duct Cancer market, the leading clinics and hospitals are prioritizing the integration of multidisciplinary treatment, advanced diagnostic imaging, and personalized care models. The most advanced cancer specialty centers are investing in surgery, AI-assisted radiology, to enhance clinical outcome. The bile duct cancer market is highly fragmented, with a mix of regional cancer institutes, multispecialty hospitals and specialized clinics offering bile duct cancer diagnosis and treatment. 'Memorial Sloan Kettering Cancer Center (MSK)', 'The University of Texas MD Anderson Cancer Center', 'City of Hope', 'Mass General Brigham Incorporated', 'Scripps Health', 'Moffitt', 'Cleveland Clinic', 'Winship Cancer Institute of Emory University', 'penn Medicine (Abramson Cancer Center)', 'University Hospitals', 'Kokilaben Dhirubhai Ambani Hospital', 'Apollo Hospitals', 'BLK-Max Super Speciality Hospital', 'Max Healthcare', 'Mayo Clinic', 'Dana-Farber Cancer Institute', 'Johns Hopkins Hospital', 'Mount Sinai Hospital', 'UCSF Health-UCSF Medical Center', 'UCLA Medical Center'

The rise in prevalence of bile duct cancer and increase in geriatric population surge the growth of the market. Aging people are more vulnerable to cancer due to weaken of immune system, and longer exposure to risk factors such as liver infection, and chronic liver disease. Cancer incidence and deaths are projected to rise significantly among old age individuals, reaching around 20.7 million new cases and 12.7 million deaths by 2040.

Short-Term: In the short term, the rise in awareness among population regarding early diagnosis and customized treatment will drive the growth of the market. In addition, the advancement in diagnostic technologies such as molecular profiling and AI-assisted image, will enhance the treatment efficiency. Furthermore, the increasing focus on precision medicine and the development of targeted therapies will boost the market expansion, which provide patient with more tailored and effective treatment.

Why is Asia Pacific Leading Bile Duct Cancer Market in 2024?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Bile Duct Cancer Market
Bile Duct Cancer Market

Report ID: SQMIG35I2376

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE